GENELUX Corp
GNLX evidence brief
What we can confirm
- BioSniper Score:
- 5.6 / 10
- Market Cap:
- $112.7M
- Lead Asset:
- olvi-vec (Phase 3)
What it means
What to watch
Prepared research question
What matters most for GNLX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GNLX
GENELUX Corp (GNLX) is a late clinical-stage immuno-oncology company developing oncolytic virus-based therapies, primarily its lead candidate Olvi-Vec, with a registrational Phase 3 trial in platinum-resistant ovarian cancer (OnPrime/GOG-3076) expected to read out in the second half of 2026.
Key risk: Single-pipeline dependency
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials for GENELUX Corp.
GENELUX Corp (GNLX) is a late clinical-stage immuno-oncology company developing oncolytic virus-based therapies, primarily its lead candidate Olvi-Vec, with a registrational Phase 3 trial in platinum-resistant ovarian cancer (OnPrime/GOG-3076) expected to read out in the second half of 2026.
- Lead product Olvi-Vec is a proprietary oncolytic vaccinia virus (VACV) being evaluated in a Phase 3 registrational trial (OnPrime/GOG-3076) for platinum-resistant/refractory ovarian cancer, with topline data expected in 2H26 [news · 2026-08-13].
- Cash & equivalents were $9.2M as of 2026-06-30, with net income of -$9.5M and shareholders' equity of $16.1M for the same period [sec].
- The company has raised net proceeds of approximately $37.8M (IPO + PIPE in 2023), $27.7M (public offering in 2024), and $9.6M (public offering in March 2025) [sec_mda · 2025-11-05].
- Phase 1b/2 VIRO-15 translational analyses in heavily pre-treated ovarian cancer patients showed an ORR of 54% (95% CI, 33%-74%) and DOR of 7.6 months (95% CI, 3.7-9.6 months) [catalyst · 2023-07-01].
- Systemic (intravenous) Olvi-Vec is also being studied in lung cancer (SCLC and NSCLC), with interim data from dose-escalation cohorts showing a 60% disease control rate (3/5 patients) as of December 31, 2025 [sec_mda · 2026-05-07].
What works
- Olvi-Vec has demonstrated a 54% ORR in a Phase 2 trial (VIRO-15) in heavily pre-treated platinum-resistant ovarian cancer, suggesting potential to overcome resistance biology [catalyst · 2023-07-01].
- The company has a proprietary discovery platform (CHOICE) enabling development of a library of oncolytic VACV immunotherapeutic candidates for multiple tumor types and delivery routes [sec_mda · 2026-08-13].
- GENELUX has successfully completed multiple public offerings (IPO, PIPE, and follow-on offerings) raising over $75M in net proceeds since 2023 to fund clinical development [sec_mda · 2025-11-05].
- The Phase 3 OnPrime/GOG-3076 trial is a registrational study, meaning positive results could directly support a Biologics License Application (BLA) for Olvi-Vec [news · 2026-08-13].
What to weigh
- The company has no approved products and no revenue from commercial product sales; it is entirely dependent on successful clinical development and regulatory approval [sec_mda · 2026-05-07].
- Cash & equivalents have declined from $21.0M (September 30, 2025) to $9.2M (June 30, 2026), indicating a significant cash burn rate [news · 2025-11-06] [sec].
- Net loss was -$9.5M for the quarter ended June 30, 2026, and the company expects cash to last only into early 2027 based on prior guidance [sec] [sec_mda · 2026-05-07].
- The Phase 3 ovarian cancer trial is a high-risk binary event; failure to meet endpoints would be a major setback given the company's focus on this single registrational program [news · 2026-08-13].
From the filings
Quoted directly from source documents.
Olvi-Vec is a stable DNA virus with large engineering capacity, developed via the CHOICE platform.
“V), a stable DNA virus with a large engineering capacity. Employing our proprietary selection technology and discovery and development platform (CHOICE), we have developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates.”
SEC MD&A · August 13, 2026
Phase 2 VIRO-15 trial in ovarian cancer showed 54% ORR and 7.6 months DOR.
“Overall, ORR by RECIST 1.1 was 54% (95% CI, 33%-74%), with a DOR of 7.6 months (95% CI, 3.7-9.6 months).”
Catalysts · July 1, 2023
Cash runway was expected into first quarter of 2027 as of March 31, 2026.
“We expect our cash, cash equivalents, restricted cash and marketable securities, totaling $26.3 million at March 31, 2026, to last into the first quarter of 2027.”
SEC MD&A · May 7, 2026
Topline Phase 3 data expected in second half of 2026.
“Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26”
News · August 13, 2026
Catalyst timeline
- 2026-12-31 · Phase 3 OnPrime/GOG-3076 topline data readout — This is the registrational trial for Olvi-Vec in platinum-resistant ovarian cancer; positive results would be a major value inflection point.
- 2026-12-31 · Systemic Olvi-Vec dose-escalation updates — Additional interim data from lung cancer (SCLC/NSCLC) trials are expected, which could inform the broader pipeline potential.
Risks & what to watch (4)›
Key risks
- Single-pipeline dependency — The company's near-term value hinges on the Phase 3 OnPrime trial; failure would leave no late-stage backup [news · 2026-08-13].
- Cash runway constraint — Cash of $9.2M as of June 30, 2026, with net losses of $9.5M/quarter, suggests runway may be under 12 months without new financing [sec].
- No commercial revenue — The company has no approved products and will not generate product revenue until regulatory approval, which is uncertain [sec_mda · 2026-05-07].
- Clinical trial execution risk — Systemic lung cancer programs are still in early dose-escalation (5 evaluable patients), with limited data to support registrational path [sec_mda · 2026-05-07].
What to watch
- Topline data from the Phase 3 OnPrime/GOG-3076 ovarian cancer trial expected in 2H26 [news · 2026-08-13].
- Additional dose-escalation updates from systemic Olvi-Vec lung cancer programs anticipated in 2026 [news · 2026-08-13].
- Cash position and any new financing or partnership announcements given the current cash burn rate [sec].
- Potential regulatory interactions or BLA submission plans if Phase 3 results are positive [news · 2026-08-13].
Sources: Catalysts · News · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run GENELUX Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GENELUX Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.63 · 0% dilution
Lead: Phase 3
2 candidates
No upcoming catalysts tracked
0 buys · 13 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 6.9%
- Days to cover
- 12.2
- Shares short
- 3,020,978
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GNLX short interestGovernance
Frequently asked questions
What is the AI investment thesis for GENELUX Corp?
GENELUX Corp (GNLX) is a late clinical-stage immuno-oncology company developing oncolytic virus-based therapies, primarily its lead candidate Olvi-Vec, with a registrational Phase 3 trial in platinum-resistant ovarian cancer (OnPrime/GOG-3076) expected to read out in the second half of 2026.
What is GENELUX Corp's lead drug candidate?
GENELUX Corp's most advanced tracked candidate is olvi-vec (Phase 3) for Ovarian Cancer.
Who is the CEO of GENELUX Corp?
Mr. Thomas D. Zindrick J.D. is the chief executive officer of GENELUX Corp (GNLX).
Where is GENELUX Corp headquartered?
GENELUX Corp (GNLX) is headquartered in Westlake Village, CA, United States.
What therapeutic areas does GENELUX Corp focus on?
GENELUX Corp develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.